Loading
A cohort of about 100,000 women having mammograms whose blood GRAIL stored to check its multi-cancer test against the cancers that appeared over the next year.
STRIVE (NCT03085888) is an observational study sponsored by GRAIL, Inc. Its registry purpose is to evaluate the pre-specified GRAIL test for invasive cancers, including blood cancers, diagnosed within one year of the first blood draw, and to refine the classifier and its cut-offs.
The registry record, read on 29 October 2026, gives its status as completed, with 99,481 participants enrolled, a start on 28 February 2017 and primary completion on 30 June 2022.
Shares GRAIL, Galleri, Multi-cancer early detection (MCED), Liquid biopsy (ctDNA).
Shares GRAIL, Galleri, Multi-cancer early detection (MCED), Liquid biopsy (ctDNA).
Shares GRAIL, Galleri, Multi-cancer early detection (MCED), Liquid biopsy (ctDNA).
Shares GRAIL, Galleri, Multi-cancer early detection (MCED), Liquid biopsy (ctDNA).
Shares GRAIL, Galleri, Multi-cancer early detection (MCED), Liquid biopsy (ctDNA).
Shares GRAIL, Galleri, Multi-cancer early detection (MCED), Liquid biopsy (ctDNA).
Shares GRAIL, Galleri, Multi-cancer early detection (MCED), Liquid biopsy (ctDNA).
Shares Sensitive and specific multi-cancer detection and localization using methylation signatures in cell-free DNA, GRAIL, Galleri, Multi-cancer early detection (MCED).
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/